Dr. Paul Richardson of @danafarber.bsky.social presents results from SUCCESSOR-2 study showing the oral drug mezigdomide markedly improved PFS in patients w/relapsed or refractory multiple myeloma. Results support this novel therapy as a possible new standard of care for RRMM. #ASCO26 bit.ly/4wUzw6z
